About CTI BioPharma Corp. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:CTIC
- CUSIP: N/A
- Web: www.ctibiopharma.com
Capitalization:- Market Cap: $105.96 million
- Outstanding Shares: 31,725,000
Average Prices:- 50 Day Moving Avg: $3.26
- 200 Day Moving Avg: $3.60
- 52 Week Range: $0.36 - $6.48
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.79
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $36.55 million
- Price / Sales: 2.90
- Book Value: $1.37 per share
- Price / Book: 2.44
Profitability:- EBITDA: ($50,380,000.00)
- Net Margins: -136.76%
- Return on Equity: -418.99%
- Return on Assets: -73.69%
Debt:- Debt-to-Equity Ratio: 0.19%
- Current Ratio: 2.15%
- Quick Ratio: 2.11%
Misc:- Average Volume: 166,223 shs.
- Beta: 0.83
- Short Ratio: 4.23
Frequently Asked Questions for CTI BioPharma Corp. (NASDAQ:CTIC)
What is CTI BioPharma Corp.'s stock symbol?
CTI BioPharma Corp. trades on the NASDAQ under the ticker symbol "CTIC."
When did CTI BioPharma Corp.'s stock split? How did CTI BioPharma Corp.'s stock split work?
CTI BioPharma Corp. shares reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma Corp. stock prior to the reverse split would have 10 shares after the split.
How were CTI BioPharma Corp.'s earnings last quarter?
CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings data on Thursday, August, 3rd. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.60) by $0.63. The business had revenue of $22.23 million for the quarter. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. View CTI BioPharma Corp.'s Earnings History.
When will CTI BioPharma Corp. make its next earnings announcement?
Where is CTI BioPharma Corp.'s stock going? Where will CTI BioPharma Corp.'s stock price be in 2017?
1 equities research analysts have issued twelve-month price targets for CTI BioPharma Corp.'s shares. Their forecasts range from $7.50 to $7.50. On average, they anticipate CTI BioPharma Corp.'s stock price to reach $7.50 in the next year. View Analyst Ratings for CTI BioPharma Corp..
Who are some of CTI BioPharma Corp.'s key competitors?
Some companies that are related to CTI BioPharma Corp. include Chromadex Corp (CDXC), Compugen (CGEN), Nabriva Therapeutics AG (NBRV), Merrimack Pharmaceuticals (MACK), Pluristem Therapeutics (PSTI), Advaxis (ADXS), Silence Therapeutics plc (SLN), Organovo Holdings (ONVO), Organovo Holdings (ONVO), CASI Pharmaceuticals (CASI), Oramed Pharmaceuticals (ORMP), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Regulus Therapeutics (RGLS), Infinity Pharmaceuticals (INFI), Palatin Technologies (PTN) and GTx (GTXI).
Who are CTI BioPharma Corp.'s key executives?
CTI BioPharma Corp.'s management team includes the folowing people:
- Richard L. Love, Interim Chairman of the Board
- Adam R. Craig M.D., Ph.D., President, Chief Executive Officer, Director
- Bruce J. Seeley, Principal Financial Officer, Executive Vice President, Chief Commercial and Administrative Officer, Secretary
- Jack W. Singer M.D., Interim Chief Medical Officer, Global Head of Translational Medicine, Executive Vice President, Chief Scientific Officer
- Nancy L. Boman Ph.D., Senior Vice President of Clinical Development and Regulatory Affairs
- Monique M. Greer, Senior Vice President of Corporate Communications and Investor Relations
- Michael A. Metzger, Director
- Matthew Perry, Director
- Laurent Fischer M.D., Independent Director
- David Ross Parkinson M.D., Independent Director
How do I buy CTI BioPharma Corp. stock?
Shares of CTI BioPharma Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CTI BioPharma Corp.'s stock price today?
One share of CTI BioPharma Corp. stock can currently be purchased for approximately $3.34.
MarketBeat Community Rating for CTI BioPharma Corp. (NASDAQ CTIC)MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)Earnings History by Quarter for CTI BioPharma Corp. (NASDAQ CTIC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2017 | | | | | | | | |
| 8/3/2017 | Q2 2017 | ($0.60) | $0.03 | | $22.23 million | View | Listen |  |
| 5/3/2017 | Q1 2017 | ($0.70) | ($0.71) | | $0.75 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.70) | ($0.23) | | $9.14 million | View | Listen | |
| 8/4/2016 | Q2 | ($0.10) | ($0.07) | | $7.36 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.04) | $0.01 | | $36.48 million | View | N/A | |
| 2/16/2016 | Q4 | ($0.18) | ($0.13) | | $11.32 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.12) | ($0.19) | $18.89 million | $1.00 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.10) | ($0.19) | $12.77 million | $1.10 million | View | Listen | |
| 5/6/2015 | Q115 | ($0.14) | ($0.16) | $9.84 million | $2.73 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.18) | ($0.27) | $2.48 million | $17.80 million | View | Listen | |
| 10/29/2014 | Q3 | $0.03 | $0.03 | $21.52 million | $39.53 million | View | Listen | |
| 8/4/2014 | Q2 | ($0.12) | ($0.19) | $11.79 million | $1.34 million | View | Listen | |
| 4/29/2014 | Q114 | ($0.20) | ($0.20) | $1.10 million | $1.40 million | View | N/A | |
| 3/4/2014 | Q4 | ($0.16) | $0.08 | $1.26 million | $32.90 million | View | Listen | |
| 2/28/2013 | Q4 2012 | ($0.20) | ($0.20) | $1.00 million | | View | Listen | |
| 11/1/2012 | Q312 | | ($0.38) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for CTI BioPharma Corp. (NASDAQ:CTIC)2017 EPS Consensus Estimate: ($0.63)
2018 EPS Consensus Estimate: ($1.84)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2017 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q4 2017 | 1 | ($0.31) | ($0.31) | ($0.31) |
| Q1 2018 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q2 2018 | 1 | ($0.31) | ($0.31) | ($0.31) |
| Q3 2018 | 1 | ($0.66) | ($0.66) | ($0.66) |
| Q4 2018 | 1 | ($0.55) | ($0.55) | ($0.55) |
(Data provided by Zacks Investment Research)
Dividend History for CTI BioPharma Corp. (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CTI BioPharma Corp. (NASDAQ:CTIC)Insider Ownership Percentage: 8.08%
Institutional Ownership Percentage: 42.87%
Insider Trades by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/29/2017 | Richard L Love | Director | Sell | 14,600 | $3.21 | $46,866.00 | |
| 6/24/2016 | James A Bianco | CEO | Sell | 10,000 | $0.37 | $3,700.00 | |
| 5/27/2016 | James A Bianco | CEO | Sell | 10,000 | $0.45 | $4,500.00 | |
| 4/29/2016 | James A Bianco | CEO | Sell | 10,000 | $0.52 | $5,200.00 | |
| 3/28/2016 | James A Bianco | CEO | Sell | 10,000 | $0.49 | $4,900.00 | |
| 3/21/2016 | James A Bianco | CEO | Sell | 318,169 | $0.55 | $174,992.95 | |
| 3/4/2016 | Matthew Plunkett | EVP | Sell | 10,000 | $0.59 | $5,900.00 | |
| 2/26/2016 | Jack W Singer | EVP | Sell | 15,000 | $0.63 | $9,450.00 | |
| 2/26/2016 | James A Bianco | CEO | Sell | 10,000 | $0.63 | $6,300.00 | |
| 2/16/2016 | James A Bianco | CEO | Sell | 100,000 | $0.42 | $42,000.00 | |
| 2/4/2016 | Matthew Plunkett | EVP | Sell | 10,000 | $1.15 | $11,500.00 | |
| 1/29/2016 | Jack W. Singer | EVP | Sell | 15,000 | $1.18 | $17,700.00 | |
| 1/29/2016 | James A Bianco | CEO | Sell | 10,000 | $1.20 | $12,000.00 | |
| 1/8/2016 | Value Fund L P Biotechnology | Insider | Buy | 1,001,327 | $1.22 | $1,221,618.94 | |
| 1/4/2016 | Matthew Plunkett | EVP | Sell | 10,000 | $1.21 | $12,100.00 | |
| 12/30/2015 | James A. Bianco | CEO | Sell | 110,000 | $1.26 | $138,600.00 | |
| 12/28/2015 | James A. Bianco | CEO | Sell | 10,000 | $1.29 | $12,900.00 | |
| 12/18/2015 | Jack W. Singer | EVP | Sell | 15,000 | $1.18 | $17,700.00 | |
| 12/4/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $1.00 | $10,000.00 | |
| 11/27/2015 | Jack W. Singer | EVP | Sell | 15,000 | $1.21 | $18,150.00 | |
| 11/27/2015 | James A Bianco | CEO | Sell | 10,000 | $1.23 | $12,300.00 | |
| 11/19/2015 | Louis A. Bianco | EVP | Sell | 15,000 | $1.13 | $16,950.00 | |
| 10/30/2015 | James A Bianco | CEO | Sell | 260,000 | $1.35 | $351,000.00 | |
| 10/29/2015 | Louis A. Bianco | EVP | Sell | 10,000 | $1.41 | $14,100.00 | |
| 10/23/2015 | Jack W. Singer | EVP | Sell | 15,000 | $1.62 | $24,300.00 | |
| 10/22/2015 | Louis A Bianco | EVP | Sell | 10,000 | $1.58 | $15,800.00 | |
| 10/5/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $1.52 | $15,200.00 | |
| 9/30/2015 | Jack W. Singer | EVP | Sell | 100,000 | $1.42 | $142,000.00 | |
| 9/30/2015 | James A. Bianco | CEO | Sell | 600,000 | $1.43 | $858,000.00 | |
| 9/30/2015 | Richard L. Love | Director | Sell | 13,660 | $1.45 | $19,807.00 | |
| 9/29/2015 | Louis A. Bianco | EVP | Sell | 170,000 | $1.41 | $239,700.00 | |
| 9/25/2015 | Jack W. Singer | EVP | Sell | 15,000 | $1.64 | $24,600.00 | |
| 9/24/2015 | Matthew Plunkett | EVP | Sell | 75,869 | $1.57 | $119,114.33 | |
| 9/4/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $1.54 | $15,400.00 | |
| 8/28/2015 | Jack W. Singer | EVP | Sell | 15,000 | $1.58 | $23,700.00 | |
| 7/24/2015 | Jack W Singer | EVP | Sell | 15,000 | $1.91 | $28,650.00 | |
| 7/23/2015 | Louis A Bianco | EVP | Sell | 10,000 | $1.91 | $19,100.00 | |
| 7/6/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $1.95 | $19,500.00 | |
| 6/26/2015 | Jack W Singer | EVP | Sell | 15,000 | $2.07 | $31,050.00 | |
| 6/25/2015 | Louis A Bianco | EVP | Sell | 10,000 | $2.18 | $21,800.00 | |
| 6/4/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $2.06 | $20,600.00 | |
| 5/22/2015 | Jack W Singer | EVP | Sell | 15,000 | $1.74 | $26,100.00 | |
| 5/21/2015 | Louis A Bianco | EVP | Sell | 10,000 | $1.80 | $18,000.00 | |
| 5/4/2015 | Matthew Plunkett | EVP | Sell | 10,000 | $1.86 | $18,600.00 | |
| 4/24/2015 | Jack W Singer | EVP | Sell | 15,000 | $1.96 | $29,400.00 | |
| 4/23/2015 | Louis A Bianco | EVP | Sell | 10,000 | $1.93 | $19,300.00 | |
| 4/6/2015 | Matthew Plunkett | EVP | Sell | 16,569 | $1.88 | $31,149.72 | |
| 3/23/2015 | James A Bianco | CEO | Sell | 175,199 | $1.95 | $341,638.05 | |
| 3/23/2015 | Matthew Plunkett | EVP | Sell | 59,130 | $1.96 | $115,894.80 | |
| 3/20/2015 | Louis A Bianco | EVP | Sell | 63,000 | $1.94 | $122,220.00 | |
| 2/27/2015 | Jack W Singer | EVP | Sell | 15,000 | $2.35 | $35,250.00 | |
| 2/5/2015 | Louis A Bianco | EVP | Sell | 10,000 | $2.22 | $22,200.00 | |
| 2/4/2015 | Matthew Plunkett | EVP | Sell | 12,000 | $2.22 | $26,640.00 | |
| 1/8/2015 | Louis A Bianco | EVP | Sell | 10,000 | $2.32 | $23,200.00 | |
| 1/5/2015 | Matthew Plunkett | EVP | Sell | 12,000 | $2.36 | $28,320.00 | |
| 12/19/2014 | James A Bianco | CEO | Sell | 40,000 | $2.44 | $97,600.00 | |
| 12/4/2014 | Louis A Bianco | EVP | Sell | 10,000 | $2.25 | $22,500.00 | |
| 11/6/2014 | Louis A Bianco | EVP | Sell | 10,000 | $2.37 | $23,700.00 | |
| 10/6/2014 | Matthew Plunkett | EVP | Sell | 12,000 | $2.39 | $28,680.00 | |
| 9/23/2014 | Matthew Plunkett | EVP | Sell | 103,635 | $2.56 | $265,305.60 | |
| 9/22/2014 | James A Bianco | CEO | Sell | 307,068 | $2.53 | $776,882.04 | |
| 9/22/2014 | Matthew Plunkett | EVP | Sell | 51,817 | $2.58 | $133,687.86 | |
| 9/19/2014 | Louis A Bianco | EVP | Sell | 145,000 | $2.59 | $375,550.00 | |
| 9/4/2014 | Matthew Plunkett | EVP | Sell | 27,301 | $2.48 | $67,706.48 | |
| 8/15/2014 | James A Bianco | CEO | Sell | 40,000 | $2.54 | $101,600.00 | |
| 8/4/2014 | Matthew Plunkett | EVP | Sell | 12,000 | $2.48 | $29,760.00 | |
| 7/10/2014 | Louis A Bianco | EVP | Sell | 10,000 | $2.73 | $27,300.00 | |
| 7/7/2014 | Matthew Plunkett | EVP | Sell | 12,000 | $2.89 | $34,680.00 | |
| 6/27/2014 | James A Bianco | CEO | Sell | 50,000 | $2.84 | $142,000.00 | |
| 6/5/2014 | Louis A Bianco | EVP | Sell | 10,000 | $2.97 | $29,700.00 | |
| 5/1/2014 | Louis Bianco | EVP | Sell | 10,000 | $2.91 | $29,100.00 | |
| 3/28/2014 | Vartan Gregorian | Director | Sell | 82,000 | $3.41 | $279,620.00 | |
| 3/25/2014 | Phillip Phd Nudelman | Director | Sell | 100,000 | $3.56 | $356,000.00 | |
| 3/24/2014 | Jack Singer | EVP | Sell | 60,000 | $3.47 | $208,200.00 | |
| 3/21/2014 | James Bianco | CEO | Sell | 395,000 | $3.83 | $1,512,850.00 | |
| 3/21/2014 | Matthew Plunkett | EVP | Sell | 170,000 | $3.73 | $634,100.00 | |
| 3/7/2014 | Fred Telling | Director | Sell | 72,095 | $3.75 | $270,356.25 | |
| 9/23/2013 | James A Bianco | CEO | Sell | 130,551 | $1.50 | $195,826.50 | |
| 8/30/2013 | James A Bianco | CEO | Sell | 25,925 | $1.08 | $27,999.00 | |
| 8/9/2013 | James A Bianco | CEO | Sell | 40,000 | $1.07 | $42,800.00 | |
| 8/7/2013 | Mary Oneil Mundinger | Director | Sell | 125,000 | $1.06 | $132,500.00 | |
| 8/6/2013 | Phillip M Phd Nudelman | Director | Sell | 50,000 | $1.09 | $54,500.00 | |
| 7/26/2013 | James A Bianco | CEO | Sell | 25,688 | $1.09 | $27,999.92 | |
| 6/28/2013 | James A Bianco | CEO | Sell | 26,053 | $1.08 | $28,137.24 | |
| 6/5/2013 | Jack W Singer | EVP | Sell | 10,000 | $1.26 | $12,600.00 | |
| 5/31/2013 | James A Bianco | CEO | Sell | 28,000 | $1.22 | $34,160.00 | |
| 5/31/2013 | Louis A Bianco | EVP | Sell | 33,712 | $1.24 | $41,802.88 | |
| 5/30/2013 | Fred Telling | Director | Sell | 64,798 | $1.24 | $80,349.52 | |
| 5/24/2013 | Richard L Love | Director | Sell | 23,000 | $1.21 | $27,830.00 | |
| 5/10/2013 | James A Bianco | CEO | Sell | 25,000 | $1.16 | $29,000.00 | |
| 5/9/2013 | Louis A Bianco | EVP | Sell | 50,000 | $1.15 | $57,500.00 | |
| 3/11/2013 | Jack W Singer | EVP | Sell | 13,000 | $1.28 | $16,640.00 | |
| 8/10/2012 | James A Bianco | CEO | Sell | 10,000 | $0.42 | $4,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for CTI BioPharma Corp. (NASDAQ:CTIC)
Latest Headlines for CTI BioPharma Corp. (NASDAQ:CTIC)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to CTI BioPharma Corp. : October 16, 2017
finance.yahoo.com - October 16 at 6:21 PM |
 | ValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong Sell
www.americanbankingnews.com - October 11 at 10:26 PM |
| CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 6:44 AM |
| ETFs with exposure to CTI BioPharma Corp. : October 2, 2017
finance.yahoo.com - October 3 at 6:44 AM |
| CTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in Stock
www.americanbankingnews.com - October 2 at 8:02 PM |
| CTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in August
www.americanbankingnews.com - September 17 at 1:20 AM |
| CTI BioPharma Corp. Forecasted to Post Q3 2017 Earnings of ($0.32) Per Share (CTIC)
www.americanbankingnews.com - September 14 at 7:33 AM |
 | Pre-Open Movers 09/12: (ALDX) (QTNT) (CTIC) Higher; (SAGE) (ICPT) (HIIQ) Lower (more...)
www.streetinsider.com - September 12 at 6:17 PM |
| Jefferies Group LLC Begins Coverage on CTI BioPharma Corp. (CTIC)
www.americanbankingnews.com - September 12 at 9:24 AM |
 | CTI BioPharma (CTIC) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow
seekingalpha.com - September 11 at 6:18 PM |
 | CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference - PR Newswire (press release)
www.prnewswire.com - August 31 at 10:52 PM |
| CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference
finance.yahoo.com - August 31 at 4:46 AM |
 | 20 Stocks Moving In Friday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - August 18 at 10:46 PM |
| CTI Biopharma's Pacritinib: Where We Stand Today - Seeking Alpha
seekingalpha.com - August 14 at 6:00 PM |
| CTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM |
| CTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM |
| Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM |
| Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM |
| CTI BioPharma Corp. (NASDAQ:CTIC) Releases Earnings Results, Beats Estimates By $0.63 EPS
www.americanbankingnews.com - August 3 at 7:02 PM |
 | EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q2 Earnings Report
www.rttnews.com - August 3 at 7:01 PM |
| Investor Network: CTI BioPharma Corp. to Host Earnings Call
finance.yahoo.com - August 3 at 7:01 PM |
| CTI BioPharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:01 PM |
| CTI BioPharma posts 2Q profit
finance.yahoo.com - August 3 at 7:01 PM |
| CTI BioPharma Announces First Patient Enrolled in...
www.benzinga.com - August 2 at 11:32 PM |
| CTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib
www.streetinsider.com - August 2 at 11:32 PM |
| CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who ... - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:29 PM |
| CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
finance.yahoo.com - August 2 at 4:18 AM |
| CTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib - StreetInsider.com
www.streetinsider.com - August 1 at 11:17 PM |
| CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
finance.yahoo.com - August 1 at 3:34 AM |
| CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - July 27 at 2:28 AM |
| CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, MD, to Board of Directors - PR Newswire (press release)
www.prnewswire.com - July 25 at 5:35 PM |
| CTI BioPharma (CTIC) Appoints Veteran Laurent Fischer, MD, to Board of Directors - StreetInsider.com
www.streetinsider.com - July 24 at 10:59 AM |
| CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
finance.yahoo.com - July 24 at 10:59 AM |
 | CTI BioPharma Gains European Medicines Nod - Baystreet.ca
www.baystreet.ca - July 15 at 1:28 AM |
| 3 Things In Biotech You Should Learn Today: July 14, 2017
seekingalpha.com - July 14 at 8:27 PM |
 | FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue ... - Nasdaq
www.nasdaq.com - July 14 at 3:26 PM |
| CTI BioPharma (CTIC) Announces EMA Validation of Pacritinib MAA ... - StreetInsider.com
www.streetinsider.com - July 14 at 3:26 PM |
| FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33%
www.rttnews.com - July 14 at 4:56 AM |
| CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application ... - PR Newswire (press release)
www.prnewswire.com - July 13 at 6:47 PM |
| CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
finance.yahoo.com - July 13 at 6:47 PM |
| Analysts Expect CTI BioPharma Corp. (CTIC) to Announce -$0.70 Earnings Per Share
www.americanbankingnews.com - July 5 at 12:22 AM |
| Premarket Gainers as of 9:05 am - Seeking Alpha
seekingalpha.com - June 15 at 11:28 PM |
| CTI BioPharma Receives $10 Million Milestone Payment for ... - PR Newswire (press release)
www.prnewswire.com - June 15 at 11:28 PM |
| Pre-Open Movers 06/15: (HTGM) (CTIC) (YTRA) Higher; (KR) (ARNA) (GOOGL) Lower (more...)
www.streetinsider.com - June 15 at 6:28 PM |
| CTI Hikes on Teva Milestone Payment
www.baystreet.ca - June 15 at 6:28 PM |
| BUZZ-U.S. STOCKS ON THE MOVE-CTi BioPharma, Epizyme, Western Digital
www.nasdaq.com - June 15 at 6:28 PM |
| CTI BioPharma (CTIC) Announces Public Offering Of Convertible Preferred Stock - StreetInsider.com
www.streetinsider.com - June 7 at 4:47 PM |
| CTI BioPharma (CTIC) Announces Public Offering Of Convertible Preferred Stock
www.streetinsider.com - June 6 at 2:36 AM |
| EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q1 Earnings Report
www.rttnews.com - May 5 at 2:44 AM |
| CTI BioPharma Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 3 at 4:30 PM |
CTI BioPharma Corp. (CTIC) Chart for Wednesday, October, 18, 2017
